Drug Trial Radar · NCT07927010
A Clinical Trial to Evaluate the Efficacy and Safety of Bevemipretide Ophthalmic Topical Solution in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Mar 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- Mighty Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Approximately 300 subjects with eligible dry AMD will be randomized to one of three groups (low dose Bevemipretide, high dose Bevemipretide, or vehicle) to receive daily ophthalmic solution administration for 48 weeks.
Conditions
- Dry AMD
- Age-Related Macular Degeneration (AMD)
Interventions
1 % BevemipretideDrug
Low Dose 1% bevemipretide ophthalmic topical solution
2% BevemipretideDrug
High Dose 2% bevemipretide ophthalmic topical solution
VehicleOther
Vehicle for this trial will be composed of sodium chloride and phosphate buffer, similar to excipients used to manufacture the active drug, but without the active drug substance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Change in Macular Area of Photoreceptor Loss through week 48Time frame: 48 Weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.